室性心动过速:导管消融还是抗心律失常药物
这项国际随机试验将416例既往心肌梗死、临床显著室性心动过速(室速风暴、ICD恰当放电或抗心动过速起搏、需急诊终止的持续性室速)且均植入ICD的患者按1:1随机分配至抗心律失常药物治疗组或导管消融组,消融在随机化后14天内完成,根据预设标准选用索他洛尔或胺碘酮。中位随访4.3年,消融组203例中103例(50.7%)发生主要终点事件,药物组213例中129例(60.6%)发生(HR 0.75;95%CI 0.58~0.97;P=0.03)。消融组术后30天内死亡2例(1.0%)、非致死性不良事件23例(11.3%);药物组归因于抗心律失常药物治疗的死亡1例(0.5%,肺毒性)、非致死性不良事件46例(21.6%)。
要点
- 缺血性心肌病合并临床显著室速且已植入ICD者,一线导管消融较索他洛尔/胺碘酮降低复合终点风险(50.7% vs 60.6%,HR 0.75;95%CI 0.58~0.97;P=0.03)。
- 主要终点为全因死亡或随机化14天后室速风暴、ICD恰当放电、需医疗干预的持续性室速的复合终点。
- 消融组术后30天内死亡2例(1.0%)、非致死性不良事件23例(11.3%)。
- 药物组归因于抗心律失常药的死亡1例(0.5%,肺毒性)、非致死性不良事件46例(21.6%)。
适用人群与场景
- 既往心肌梗死并临床显著室性心动过速(室速风暴、ICD恰当放电或抗心动过速起搏、需急诊终止的持续性室速)的患者,均植入ICD。
- 国际多中心随机试验人群,随机化后随访中位4.3年。
诊断标准与关键阈值
- 临床显著室性心动过速定义为:室速风暴、接受ICD恰当放电或抗心动过速起搏、或需急诊治疗终止的持续性室速。
处置流程与药物剂量
- 导管消融组:随机化后14天内行导管消融。
- 抗心律失常药物组:根据预设标准给予索他洛尔或胺碘酮。
研究设计与关键结果
- 国际随机对照试验,416例患者按1:1随机分配至导管消融组(203例)或抗心律失常药物组(213例),中位随访4.3年。
- 主要终点事件:消融组103/203例(50.7%)vs 药物组129/213例(60.6%)(HR 0.75;95%CI 0.58~0.97;P=0.03)。
- 消融组术后30天内不良事件:死亡2例(1.0%),非致死性不良事件23例(11.3%)。
- 药物组归因于抗心律失常药物治疗的不良事件:肺毒性死亡1例(0.5%),非致死性不良事件46例(21.6%)。
证据类型、等级与局限
- 研究类型:国际随机对照试验(VANISH2,NCT02830360)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于既往心肌梗死、临床显著室速且已植入ICD的患者,作者认为初始采用导管消融策略较抗心律失常药物治疗可降低复合主要终点事件风险。
指南或共识出处
- VANISH2 试验(ClinicalTrials.gov NCT02830360),由加拿大健康研究院等资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with ventricular tachycardia and ischemic cardiomyopathy are at high risk for adverse outcomes. Catheter ablation is commonly used when antiarrhythmic drugs do not suppress ventricular tachycardia. Whether catheter ablation is more effective than antiarrhythmic drugs as a first-line therapy in patients with ventricular tachycardia is uncertain.
METHODS: In an international trial, we randomly assigned in a 1:1 ratio patients with previous myocardial infarction and clinically significant ventricular tachycardia (defined as ventricular tachycardia storm, receipt of appropriate implantable cardioverter-defibrillator [ICD] shock or antitachycardia pacing, or sustained ventricular tachycardia terminated by emergency treatment) to receive antiarrhythmic drug therapy or to undergo catheter ablation. All the patients had an ICD. Catheter ablation was performed within 14 days after randomization; sotalol or amiodarone was administered as antiarrhythmic drug therapy according to prespecified criteria. The primary end point was a composite of death from any cause during follow-up or, more than 14 days after randomization, ventricular tachycardia storm, appropriate ICD shock, or sustained ventricular tachycardia treated by medical intervention.
RESULTS: A total of 416 patients were followed for a median of 4.3 years. A primary end-point event occurred in 103 of 203 patients (50.7%) assigned to catheter ablation and in 129 of 213 (60.6%) assigned to drug therapy (hazard ratio, 0.75; 95% confidence interval, 0.58 to 0.97; P = 0.03). Among patients in the catheter ablation group, adverse events within 30 days after the procedure included death in 2 patients (1.0%) and nonfatal adverse events in 23 patients (11.3%). Among the patients assigned to drug therapy, adverse events that were attributed to antiarrhythmic drug treatment included death from pulmonary toxic effects in 1 patient (0.5%) and nonfatal adverse events in 46 patients (21.6%).
CONCLUSIONS: Among patients with ischemic cardiomyopathy and ventricular tachycardia, an initial strategy of catheter ablation led to a lower risk of a composite primary end-point event than antiarrhythmic drug therapy. (Funded by the Canadian Institutes of Health Research and others; VANISH2 ClinicalTrials.gov number, NCT02830360.).
参考来源
- Sapp JL, Tang ASL, Parkash R, et al. Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia. N Engl J Med. 2024. PMID: 39555820. doi:10.1056/NEJMoa2409501
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。